Related Experiment Videos
Shared Decision Making: Aids and Promotion in Clinical Practice Guidelines for Type 2 Diabetes Treatment
Yves Marie Vincent1, Merwan Kasbi2, Reda Saouli2
1Department of General Medicine, Bordeaux University, Bordeaux, France.
Introduction:
Type 2 diabetes (T2D) is a major global health issue due to its rising prevalence and significant burden in terms of morbidity, mortality, and economic impact. Although the availability of Clinical Practice Guidelines (CPGs) aimed at optimising T2D management, the complexity of therapeutic options and the necessity of tailoring treatment to individual patient preferences pose ongoing challenges. Shared Decision Making (SDM) and the high-quality decision aids have been shown to enhance patient understanding and engagement in medical decisions. This study aimed to assess the presence of decision aids and the promotion of SDM within international and national CPGs for T2D treatment.
Methods:
Fifty-two CPGs identified in a prior systematic review were re-evaluated. Following the application of exclusion criteria and review of updates, 33 CPGs from 20 countries were included. The analysis focused on identifying high-quality decision aids-defined as those providing absolute risk estimates for therapeutic options-and on detecting explicit support for SDM using predefined key terms.
Results:
No CPGs included decision aids that met the criteria for high quality. However, 73% acknowledged the importance of patient values and preferences, incorporating at least one reference to SDM. Despite this, no tools were provided to facilitate the practical implementation of SDM. This finding underscores a persistent gap between the theoretical recognition of SDM and its operational integration into CPGs.
Discussion:
These findings suggest that although the role of SDM is theoretically embraced, its practical application remains insufficient. Efforts from major guideline-developing organisations to improve methodological inclusion of patient-centred elements are encouraging, yet much progress is needed. Future guideline development must prioritise the integration of rigorously designed decision aids to truly support informed, value-based medical decisions in T2D care.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes III: Clinical Manifestations
Type II Diabetes II: Pathophysiology